George Poste Sells 11,686 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director George Poste sold 11,686 shares of the business's stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total transaction of $244,938.56. Following the completion of the sale, the director now owns 213,907 shares of the company's stock, valued at $4,483,490.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Exelixis Stock Performance

Shares of EXEL stock traded down $0.02 during mid-day trading on Wednesday, reaching $21.00. The company's stock had a trading volume of 1,528,552 shares, compared to its average volume of 2,266,373. Exelixis, Inc. has a 1-year low of $18.64 and a 1-year high of $24.34. The company has a market cap of $6.37 billion, a P/E ratio of 32.81, a PEG ratio of 0.57 and a beta of 0.57. The firm's 50-day moving average is $22.74 and its two-hundred day moving average is $22.30.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by ($0.16). Exelixis had a net margin of 11.10% and a return on equity of 8.85%. The business had revenue of $425.23 million during the quarter, compared to analyst estimates of $461.04 million. During the same quarter in the prior year, the company posted $0.12 EPS. The company's quarterly revenue was up 4.0% compared to the same quarter last year. Sell-side analysts anticipate that Exelixis, Inc. will post 1.16 EPS for the current year.

Institutional Investors Weigh In On Exelixis

Several large investors have recently made changes to their positions in the company. Fifth Third Bancorp grew its holdings in shares of Exelixis by 44.2% in the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company's stock worth $43,000 after purchasing an additional 604 shares during the last quarter. Alaska Permanent Fund Corp grew its holdings in shares of Exelixis by 1.2% in the 1st quarter. Alaska Permanent Fund Corp now owns 53,239 shares of the biotechnology company's stock worth $1,263,000 after purchasing an additional 617 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Exelixis by 17.1% in the 3rd quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 668 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 728 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its holdings in shares of Exelixis by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 145,343 shares of the biotechnology company's stock worth $3,176,000 after purchasing an additional 738 shares during the last quarter. Institutional investors own 85.27% of the company's stock.

Analyst Upgrades and Downgrades

EXEL has been the subject of a number of analyst reports. Stephens initiated coverage on shares of Exelixis in a research note on Tuesday, May 14th. They issued an "equal weight" rating and a $23.00 price objective for the company. Stifel Nicolaus upped their target price on shares of Exelixis from $23.00 to $25.00 and gave the company a "hold" rating in a research note on Friday, February 2nd. William Blair reiterated an "outperform" rating on shares of Exelixis in a research note on Wednesday, May 1st. TD Cowen upped their target price on shares of Exelixis from $25.00 to $27.00 and gave the company a "buy" rating in a research note on Wednesday, May 1st. Finally, Royal Bank of Canada upped their target price on shares of Exelixis from $26.00 to $28.00 and gave the company an "outperform" rating in a research note on Wednesday, February 7th. Seven analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Exelixis has an average rating of "Moderate Buy" and a consensus price target of $26.13.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.